Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-30T15:22:47.886Z Has data issue: false hasContentIssue false

P-1133 - Combining Group Psychodynamic Psychotherapy With Pharmacotherapy to Treat Target Symptoms of Iranian Psychiatric Outpatients

Published online by Cambridge University Press:  15 April 2020

M. Sanati
Affiliation:
Dynamic Psychotherapy & Human Studies Unit, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
M. Moinalghorabaei
Affiliation:
Dynamic Psychotherapy & Human Studies Unit, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
J. Bakhshaie
Affiliation:
Dynamic Psychotherapy & Human Studies Unit, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
M.M. Shafiei
Affiliation:
Department of Statistics & Mathematics, Acadia University, Wolfville, NS, Canada
M. Tabatabaee
Affiliation:
Dynamic Psychotherapy & Human Studies Unit, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
F. Golriz
Affiliation:
Dynamic Psychotherapy & Human Studies Unit, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran Tehran University of Medical Sciences, Tehran, Iran

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Group psychodynamic psychotherapy (GPP) has shown some promising evidences to ameliorate the target symptoms of psychiatric patients.

Objectives

To examine the efficacy of adding GPP to pharmacotherapy treatment of Mixed anxiety-depressive disorder outpatients.

Aims

To investigate into the symptom relief effects of GPP in a developing setting.

Method

21 psychiatric outpatients who entered long-term group psychodynamic psychotherapy plus pharmacotherapy protocol (Combined therapy) and 22 psychiatric outpatients who entered pharmacotherapy alone protocol of a psychotherapy clinic in the capital (Tehran), were matched against each other and analyzed on an intent to treat basis. HAM-D-24 Q, and HAM-A were used to rate the symptoms at baseline and after 6 months of each therapy (Dropouts reported < 5%). The percentile reduction in symptom scores and the response rates for each group were compared. Age, sex and baseline depressive and anxiety scores were also examined for their confounding effect on the response rate of patients.

Results

Compared with pharmacotherapy alone, Combined therapy caused more reduction in both depressive (53% vs. 44%) and anxiety (54% vs. 45%) symptoms and also a greater response rate (62% vs. 38%) among participants. Although not significant, the asymmetric distribution of 95% confidence interval rates of the difference (PROP test,R) indicated a higher proportional response rate for combined therapy. No confounding effect was found for proposed variables.

Conclusion

The results for combining GPP with pharmacotherapy to improve the symptomatic outcome of Iranian psychiatric outpatients are in line with the developed settings studies.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.